Brinzolamide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Brinzolamide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name = (5''R'')-5-ethylamino-3-(3-methoxypropyl)-<br />2,2-dioxo-2λ<sup>6</sup>,9-dithia-<br />3-azabicyclo[4.3.0]nona-7,10-diene-<br />8-sulfonamide
{{Brinzolamide}}
| image = Brinzolamide.svg
{{CMG}}; {{AE}} {{SS}}
| CAS_number = 138890-62-7
 
| ATC_prefix = S01
'''''For patient information about Brinzolamide, click [[Brinzolamide (patient information)|here]].'''''
| ATC_suffix = EC04
 
| ATC_supplemental =  
{{SB}} AZOPT<sup>®</sup>
| PubChem = 68844
 
| DrugBank = APRD00475
==Overview==
| C=12 | H=21 | N=3 | O=5 | S=3
 
| molecular_weight = 383.51 g/mol
'''Brinzolamide''' (trade name '''Azopt''', [[Alcon]] Laboratories, Inc.) is a [[carbonic anhydrase inhibitor]] used to lower intraocular pressure in patients with open-angle [[glaucoma]] or ocular hypertension.
| bioavailability =
==Category==
| protein_bound = ~60%
 
| metabolism =
Category:Carbonic anhydrase inhibitors;Ethers;Thienothiazines;Sulfones;Sulfonamides;Amines;Cardiovascular Drugs
| elimination_half-life = 111 days
 
| excretion =
==FDA Package Insert==
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
 
| pregnancy_US = C
====AZOPT (brinzolamide) suspension ====
| pregnancy_category =
 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
'''  [[Brinzolamide indications and usage|Indications and Usage]]'''
| legal_UK = <!-- GSL / P / POM / CD -->
'''| [[Brinzolamide dosage and administration|Dosage and Administration]]'''
| legal_US = Rx-only
'''| [[Brinzolamide dosage forms and strengths|Dosage Forms and Strengths]]'''
| legal_status =
'''| [[Brinzolamide contraindications|Contraindications]]'''
| routes_of_administration = Ophthalmic
'''| [[Brinzolamide warnings and precautions|Warnings and Precautions]]'''
| licence_EU =Azopt
'''| [[Brinzolamide adverse reactions|Adverse Reactions]]'''
| licence_US =Brinzolamide
'''| [[Brinzolamide drug interactions|Drug Interactions]]'''
}}
'''| [[Brinzolamide use in specific populations|Use in Specific Populations]]'''
'''Brinzolamide''' is a [[carbonic anhydrase]] inhibitor.
'''| [[Brinzolamide overdosage|Overdosage]]'''
'''| [[Brinzolamide description|Description]]'''
'''| [[Brinzolamide clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Brinzolamide nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Brinzolamide clinical studies|Clinical Studies]]'''
'''| [[Brinzolamide how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Brinzolamide patient counseling information|Patient Counseling Information]]'''
'''| [[Brinzolamide labels and packages|Labels and Packages]]'''
 
==Mechanism of Action==
 
[[Carbonic anhydrase]] (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
 
AZOPT® (brinzolamide ophthalmic suspension) 1% contains brinzolamide, an inhibitor of [[carbonic anhydrase]] II (CA-II). Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated [[intraocular pressure]] is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.


==References==
==References==
* {{cite journal | author = Ermis S, Ozturk F, Inan U | title = Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification. | journal = Eye | volume = 19 | issue = 3 | pages = 303-7 | year = 2005 | id = PMID 15258611}}
 
* {{cite journal | author = Iester M, Altieri M, Michelson G, Vittone P, Traverso C, Calabria G | title = Retinal peripapillary blood flow before and after topical brinzolamide. | journal = Ophthalmologica | volume = 218 | issue = 6 | pages = 390-6 | year = | id = PMID 15564757}}
{{reflist|2}}
* {{cite journal | author = Kaup M, Plange N, Niegel M, Remky A, Arend O | title = Effects of brinzolamide on ocular haemodynamics in healthy volunteers. | journal = Br J Ophthalmol | volume = 88 | issue = 2 | pages = 257-62 | year = 2004 | id = PMID 14736787}}


{{Antiglaucoma preparations and miotics}}
{{Antiglaucoma preparations and miotics}}


[[Category:Carbonic anhydrase inhibitors]]
[[Category:Carbonic anhydrase inhibitors]]
 
[[Category:Ethers]]
 
[[Category:Thienothiazines]]
{{pharma-stub}}
[[Category:Sulfones]]
[[Category:Sulfonamides]]
[[Category:Amines]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Revision as of 14:56, 26 February 2014

Brinzolamide
AZOPT® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Brinzolamide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Brinzolamide, click here.

Synonyms / Brand Names: AZOPT®

Overview

Brinzolamide (trade name Azopt, Alcon Laboratories, Inc.) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Category

Category:Carbonic anhydrase inhibitors;Ethers;Thienothiazines;Sulfones;Sulfonamides;Amines;Cardiovascular Drugs

FDA Package Insert

AZOPT (brinzolamide) suspension

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).

AZOPT® (brinzolamide ophthalmic suspension) 1% contains brinzolamide, an inhibitor of carbonic anhydrase II (CA-II). Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.

References

Template:Antiglaucoma preparations and miotics

Retrieved from "https://www.wikidoc.org/index.php?title=Brinzolamide&oldid=947922"